Cargando…

Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia

Iron chelation therapy (ICT) is the mainstay of treatment in patients with thalassemia requiring blood transfusions. This phase 2 JUPITER study evaluated patient preference between film-coated tablet (FCT) and dispersible tablet (DT) in transfusion-dependent thalassemia (TDT) or non-TDT (NTDT) patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viprakasit, Vip, Hamdy, Mona M., Hassab, Hoda M. A., Sherief, Laila M., Al-Bagshi, Muneer, Khattab, Mohammed, Chuncharunee, Suporn, Dung, Phu Chi, Küpesiz, Alphan, Shekhawat, Ankita, Sonawane, Yamini, Perez, Laura Torres, Slader, Cassandra, Taher, Ali T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209569/ https://www.ncbi.nlm.nih.gov/pubmed/37227493 http://dx.doi.org/10.1007/s00277-023-05240-3

Ejemplares similares

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
por: Taher, Ali T, et al.
Publicado: (2013)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Treating iron overload in patients with non-transfusion-dependent thalassemia
por: Taher, Ali T, et al.
Publicado: (2013)

Long-Term Effectiveness, Safety, and Tolerability of Twice-Daily Dosing with Deferasirox in Children with Transfusion-Dependent Thalassemias Unresponsive to Standard Once-Daily Dosing
por: Buaboonnam, Jassada, et al.
Publicado: (2021)

Changing patterns in the epidemiology of β‐thalassemia
por: Kattamis, Antonis, et al.
Publicado: (2020)

Alterations of panoramic radiomorphometric indices in children and adolescents with beta-thalassemia major: A fractal analysis study
por: Yagmur, Burcu, et al.
Publicado: (2022)

Justification of Universal Iron Supplementation for Infants 6–12 months in Regions with a High Prevalence of Thalassemia
por: Sinlapamongkolkul, Phakatip, et al.
Publicado: (2023)

Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm
por: Musallam, Khaled M., et al.
Publicado: (2022)

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
por: Pathare, Anil, et al.
Publicado: (2009)

Non-transfusion dependent hemoglobin E/β thalassemia had high prevalence of vitamin D deficiency than more severe patients who received regular blood transfusion and iron chelation therapy
por: Nakavachara, Pairunyar, et al.
Publicado: (2013)

Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand
por: Chuncharunee, Suporn, et al.
Publicado: (2019)

Deferasirox in Indian children with thalassemia major: 3 years experience
por: Dhamija, Mayank, et al.
Publicado: (2013)

An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines
por: Ekwattanakit, Supachai, et al.
Publicado: (2021)

Effect of acetylsalicylic acid on thalassemia with pulmonary arterial hypertension
por: Chueamuangphan, Nonlawan, et al.
Publicado: (2014)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
por: Ricchi, Paolo, et al.
Publicado: (2015)

Comparison of contrast sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox
por: Ghazanfari, Azam, et al.
Publicado: (2019)

Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition
por: Viprakasit, Vip, et al.
Publicado: (2014)

Benefits of chronic blood transfusion in hemoglobin E/β thalassemia with pulmonary arterial hypertension
por: Chueamuangphan, Nonlawan, et al.
Publicado: (2014)

Prevalence of left ventricular diastolic dysfunction by cardiac magnetic resonance imaging in thalassemia major patients with normal left ventricular systolic function
por: Chinprateep, Benjaporn, et al.
Publicado: (2019)

Feasibility of and barriers to thalassemia screening in migrant populations: a cross-sectional study of Myanmar and Cambodian migrants in Thailand
por: Xu, Julia Z., et al.
Publicado: (2021)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

Efficacy and Safety of Deferasirox in Pediatric Patients of Thalassemia at a Tertiary Care Teaching Hospital
por: Thakor, Dhaval R, et al.
Publicado: (2017)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
por: Almadhani, Shaimaa, et al.
Publicado: (2023)

Spectrum of Beta Globin Gene Mutations in Egyptian Children with β-Thalassemia
por: El-Shanshory, MR, et al.
Publicado: (2014)

Identification of optimal thalassemia screening strategies for migrant populations in Thailand using a qualitative approach
por: Xu, Julia Z., et al.
Publicado: (2021)

The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan
por: Chang, Hsiu-Hao, et al.
Publicado: (2015)

Longitudinal Study on Liver Functions in Patients with Thalassemia Major before and after Deferasirox (DFX) Therapy
por: Soliman, Ashraf, et al.
Publicado: (2014)

Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha
por: Panigrahi, Mousumee, et al.
Publicado: (2020)

Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO(©))
por: Taher, Ali, et al.
Publicado: (2018)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2017)

Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO(©))
por: Taher, Ali, et al.
Publicado: (2018)

Deferasirox in thalassemia: a comparative study between an innovator drug and its copy among a sample of Iraqi patients
por: Daher, Aqil M., et al.
Publicado: (2019)

New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study
por: Taher, Ali T., et al.
Publicado: (2017)

Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major
por: Ejaz, Muzamil Shabana, et al.
Publicado: (2015)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sm6i0t4u7nm3idi3p82ac93689